Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients

Published:2021-06-16 Issue:5 Volume:23 Page:
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:Transpl Infect Dis

Author:

Kutzler Heather L.¹²^ORCID,Kuzaro Hillary A.¹²^ORCID,Serrano Oscar K.²^ORCID,Feingold Andrew²³,Morgan Glyn²,Cheema Faiqa²

Affiliation:

1. Department of Pharmacy Hartford Hospital Hartford CT USA

2. Department of Transplant and Comprehensive Liver Center Hartford Hospital Hartford CT USA

3. Center for Advanced Heart Failure and Pulmonary Vascular Disease Hartford Hospital Hartford CT USA

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tid.13662

Reference23 articles.

1. COVID‐19 in solid organ transplant recipients: Initial report from the US epicenter

2. COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes

3. COVID-19 in an international European liver transplant recipient cohort

4. Outcomes of COVID‐19 in solid organ transplants;Ranabothu S;Cureus,2020

5. COVID-19 in Solid Organ Transplant Recipients: Observations From Connecticut

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges;Cardiology in Review;2024-02-08

2. Know an Emotion by the Company It Keeps: Word Embeddings from Reddit/Coronavirus;Applied Sciences;2023-05-31

3. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19;Transplant Immunology;2023-04

4. Current and Emerging Therapies for COVID-19 in Lung Transplantation;Current Pulmonology Reports;2023-02-16

5. How to use COVID-19 antiviral drugs in patients with chronic kidney disease;Frontiers in Pharmacology;2023-02-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3